Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1999 8
2000 15
2001 23
2002 16
2003 27
2004 14
2005 18
2006 15
2007 17
2008 18
2009 15
2010 41
2011 32
2012 27
2013 28
2014 51
2015 72
2016 96
2017 82
2018 81
2019 46
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

635 results
Results by year
Filters applied: . Clear all
Page 1
Silent progression in disease activity-free relapsing multiple sclerosis.
University of California, San Francisco MS-EPIC Team, Cree BAC, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E, Bischof A, Gundel T, Zhu AH, Papinutto N, Stern WA, Bevan C, Romeo A, Goodin DS, Gelfand JM, Graves J, Green AJ, Wilson MR, Zamvil SS, Zhao C, Gomez R, Ragan NR, Rush GQ, Barba P, Santaniello A, Baranzini SE, Oksenberg JR, Henry RG, Hauser SL. University of California, San Francisco MS-EPIC Team, et al. Ann Neurol. 2019 May;85(5):653-666. doi: 10.1002/ana.25463. Epub 2019 Mar 30. Ann Neurol. 2019. PMID: 30851128 Free PMC article.
Characterization of relapsing-remitting multiple sclerosis patients using support vector machine classifications of functional and diffusion MRI data.
Zurita M, Montalba C, Labbé T, Cruz JP, Dalboni da Rocha J, Tejos C, Ciampi E, Cárcamo C, Sitaram R, Uribe S. Zurita M, et al. Neuroimage Clin. 2018;20:724-730. doi: 10.1016/j.nicl.2018.09.002. Epub 2018 Sep 4. Neuroimage Clin. 2018. PMID: 30238916 Free PMC article.
Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A; ADVANCE Study Investigators. Calabresi PA, et al. Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30. Lancet Neurol. 2014. PMID: 24794721 Clinical Trial.
Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis.
Burgetova A, Dusek P, Vaneckova M, Horakova D, Langkammer C, Krasensky J, Sobisek L, Matras P, Masek M, Seidl Z. Burgetova A, et al. AJNR Am J Neuroradiol. 2017 Jun;38(6):1079-1086. doi: 10.3174/ajnr.A5166. Epub 2017 Apr 27. AJNR Am J Neuroradiol. 2017. PMID: 28450431 Free article.
Molecular-based diagnosis of multiple sclerosis and its progressive stage.
Barbour C, Kosa P, Komori M, Tanigawa M, Masvekar R, Wu T, Johnson K, Douvaras P, Fossati V, Herbst R, Wang Y, Tan K, Greenwood M, Bielekova B. Barbour C, et al. Ann Neurol. 2017 Nov;82(5):795-812. doi: 10.1002/ana.25083. Ann Neurol. 2017. PMID: 29059494 Free PMC article.
Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis.
Grahl S, Pongratz V, Schmidt P, Engl C, Bussas M, Radetz A, Gonzalez-Escamilla G, Groppa S, Zipp F, Lukas C, Kirschke J, Zimmer C, Hoshi M, Berthele A, Hemmer B, Mühlau M. Grahl S, et al. Mult Scler Relat Disord. 2019 Apr;29:124-129. doi: 10.1016/j.msard.2019.01.042. Epub 2019 Jan 28. Mult Scler Relat Disord. 2019. PMID: 30711877
635 results
Jump to page
Feedback